$10,109.08 consulting Payment -- Novartis Pharmaceuticals to Dr. Mark Perez
Neurologist Receives Over $10,000 Consulting Fee from Novartis for Tagrisso
This page provides a detailed analysis of a $10,109.08 consulting payment from Novartis Pharmaceuticals to Dr. Mark Perez. Data is from the CMS Open Payments (Sunshine Act) database.
Payment Details
| Field | Value |
|---|---|
| Amount | $10,109.08 |
| Payment Type | consulting |
| Payment Nature | Consulting Fee |
| Pharmaceutical Company | Novartis Pharmaceuticals |
| Physician | Dr. Mark Perez |
| NPI Number | 1161548978 |
| Physician Specialty | Neurology |
| Location | City, IN |
| Date of Payment | 2026-03-06 |
| Related Drug/Device | Tagrisso |
| Conflict Assessment | Moderate -- Worth Noting |
AI-Powered Analysis of This Payment
The following analysis was generated by artificial intelligence to help patients understand the context, significance, and implications of this pharmaceutical payment. This analysis is not medical or legal advice.
Novartis Pharmaceuticals made a $10.1K consulting payment to Mark Perez, a Neurology specialist in City, IN. The payment was associated with Tagrisso. The payment of $10,109.08 to Dr. Mark Perez for consulting services related to Tagrisso is a significant amount for a single consulting engagement. This payment was made by Novartis Pharmaceuticals, a major player in the pharmaceutical industry, suggesting a focus on a key product. The payment date of March 6, 2026, indicates a future engagement, allowing for planning and potential impact on prescribing habits.
Patient Guidance: What This Payment Means for You
If you are a patient being treated with Tagrisso, understand that your doctor may receive payments from the manufacturer for consulting services, which is a standard practice in medical research and education. Always discuss your treatment options with your healthcare provider and ask about alternatives.
Payment Context: Is This Amount Normal?
A $10,109.08 consulting fee for a single engagement is on the higher end for many specialties, but may be within norms for specialized neurological consulting related to a specific drug.
Regulatory Context: Sunshine Act Requirements
Payments to physicians for consulting services are subject to disclosure under the Sunshine Act, requiring transparency in financial relationships between healthcare providers and industry.
Related Topics
This payment is related to the following healthcare transparency topics:
- pharmaceutical-payments
- consulting-fees
- neurology
- drug-marketing
- physician-compensation
- novartis
- tagrisso
Understanding consulting Payments
Consulting payments are made when pharmaceutical companies hire physicians as advisors or consultants. This can include serving on advisory boards, providing expert medical opinions on drug development or marketing strategies, and reviewing clinical data. Consulting is one of the most common forms of pharmaceutical payment to physicians and can range from a few hundred dollars for a brief consultation to tens of thousands of dollars for ongoing advisory relationships.
Frequently Asked Questions About This Payment
What was this $10.1K payment for?
This was a consulting payment of $10.1K from Novartis Pharmaceuticals to Mark Perez, categorized as "Consulting Fee". It was associated with Tagrisso. The payment was reported under the Sunshine Act (CMS Open Payments).
Does Mark Perez accept pharmaceutical money?
Yes, Mark Perez received this $10.1K payment from Novartis Pharmaceuticals. Under the Sunshine Act, pharmaceutical companies must report all payments to physicians exceeding $10. You can view Mark Perez's full payment history on the CMS Open Payments database or on this site.
Is it legal for doctors to accept pharma payments?
Yes, it is legal for physicians to receive payments from pharmaceutical companies. The Physician Payments Sunshine Act (2010) requires transparency by mandating that companies report all payments exceeding $10 to CMS. These payments include consulting fees, meals, travel, speaking fees, and research grants. The law does not prohibit payments but ensures public disclosure.
Should I be concerned about this consulting payment?
A consulting payment of $10.1K may reflect legitimate advisory services the physician provides. Payment does not imply wrongdoing, but patients have the right to ask their doctor about pharmaceutical relationships.
How do I talk to my doctor about pharma relationships?
You can ask your doctor directly: "Do you receive payments from pharmaceutical companies?" and "Does this affect which medications you prescribe?" Most doctors will answer honestly. You can also verify payment data yourself through CMS Open Payments (openpaymentsdata.cms.gov). Consider asking about generic alternatives and whether the prescribed medication is the best option regardless of manufacturer relationships.
What types of pharma payments are most concerning?
Ownership interests and large consulting/speaking fees are generally considered more significant than meals or small educational grants. Research payments typically fund clinical studies and are common in academic medicine. The total volume and concentration of payments from a single company may be more telling than any individual payment. Patterns matter more than individual transactions.
Does pharma money affect what my doctor prescribes?
Research shows that even small payments can influence prescribing behavior. Studies published in JAMA Internal Medicine found that physicians who received meals costing as little as $20 were more likely to prescribe the promoted brand-name drug. However, many physician-industry interactions are legitimate professional activities. The key is transparency and awareness.
How does this compare to other doctors in Neurology?
To compare this payment against Neurology averages, check the full specialty breakdown on CMS Open Payments. Payment amounts vary widely by specialty and type. Neurology physicians may receive payments for consulting, speaking, or research that are standard for the field. Individual payments should be evaluated in the context of the doctor's full payment history.
What does this payment reveal about Mark Perez's relationship with Novartis Pharmaceuticals?
The payment is specifically for 'Consulting Fee' under the 'consulting' payment type. This $10.1K consulting payment is part of the transparency data reported under the Sunshine Act.
Is this payment amount typical for Neurology?
Dr. Perez's specialty is Neurology, aligning with the drug Tagrisso, which is used to treat certain types of lung cancer.
What should patients do after learning about this payment?
If you are a patient being treated with Tagrisso, understand that your doctor may receive payments from the manufacturer for consulting services, which is a standard practice in medical research and education.
What else should I know about this consulting payment?
The payment ID 'OP-MNLJE6OZ-OYD3T1' is a unique identifier for this specific transaction.
Related Reports
Data from CMS Open Payments. Payment does not imply wrongdoing. Consult your healthcare provider about any concerns.